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Abstract
Background
Washington DC has a high burden of HIV with a 2.0% HIV prevalence. The city is a national
and international hub potentially containing a broad diversity of HIV variants; yet few
sequences from DC are available on GenBank to assess the evolutionary history of HIV in
the US capital. Towards this general goal, here we analyze extensive sequence data and
investigate HIV diversity, phylodynamics, and drug resistant mutations (DRM) in DC.
Methods
Molecular HIV-1 sequences were collected from participants infected through 2015 as part
of the DC Cohort, a longitudinal observational study of HIV+ patients receiving care at 13
DC clinics. Sequences were paired with Cohort demographic, risk, and clinical data and
analyzed using maximum likelihood, Bayesian and coalescent approaches of phylogenetic,
network and population genetic inference. We analyzed 601 sequences from 223 partici-
pants for int (~864 bp) and 2,810 sequences from 1,659 participants for PR/RT (~1497 bp).
Results
Ninety-nine and 94% of the int and PR/RT sequences, respectively, were identified as sub-
type B, with 14 non-B subtypes also detected. Phylodynamic analyses of US born infected
individuals showed that HIV population size varied little over time with no significant decline
in diversity. Phylogenetic analyses grouped 13.5% of the int sequences into 14 clusters of 2
or 3 sequences, and 39.0% of the PR/RT sequences into 203 clusters of 2–32 sequences.
Network analyses grouped 3.6% of the int sequences into 4 clusters of 2 sequences, and
10.6% of the PR/RT sequences into 76 clusters of 2–7 sequences. All network clusters
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were detected in our phylogenetic analyses. Higher proportions of clustered sequences
were found in zip codes where HIV prevalence is highest (r = 0.607; P<0.00001). We
detected a high prevalence of DRM for both int (17.1%) and PR/RT (39.1%), but only 8 int
and 12 PR/RT amino acids were identified as under adaptive selection. We observed a sig-
nificant (P<0.0001) association between main risk factors (men who have sex with men and
heterosexuals) and genotypes in the five well-supported clusters with sufficient sample size
for testing.
Discussion
Pairing molecular data with clinical and demographic data provided novel insights into HIV
population dynamics in Washington, DC. Identification of populations and geographic loca-
tions where clustering occurs can inform and complement active surveillance efforts to inter-
rupt HIV transmission.
Introduction
Washington, DC has consistently had one of the highest rates of HIV infection in the United
States (US) with 371 new HIV cases reported in 2015 and a 2.0% HIV prevalence [1]. The HIV
epidemic in DC is generalized: seven of the city’s eight wards (geopolitical areas) have an HIV
prevalence greater than one percent and men who have sex with men (MSM) and heterosexu-
als (HRH) account for 45% and 28% respectively of new diagnoses, with those of unknown
risk accounting for 22%. The other 3% and 2% are IDU and sexual contact/IDU, respectively
[1]. Measurement of the DC HIV continuum of care finds that approximately 11% of people
living with HIV infection (PLWH) are estimated to be unaware of their infections [2] and only
73% of persons are continuously in care with 57% of all PLWH achieving viral suppression as
of last report [1]. Given that a relatively high proportion of PLWH in care in DC have detect-
able viral loads (VL) [3] and that PLWH with VL of 1,500 copies/ml or higher are at increased
risk for transmitting virus [4], identifying those individuals is critical to ensure they are receiv-
ing appropriate antiretroviral therapy and to curbing new infections. Furthermore, DC is a
national and international city potentially containing a broad diversity of HIV variants with
11% of PLWH in DC being foreign-born [5]. Previous phylogenetic studies in the DC-Mary-
land region have found that 13% of people are infected with non-B-subtypes and of those, 81%
were from the Maryland suburbs of DC [6]. Thus, further characterization of subtype distribu-
tion will assist in determining whether there are distinct HIV epidemics occurring in the
region [6].
Started in 2011, the DC Cohort is a longitudinal observational cohort study that aims to
characterize the quality of care being received among PLWH obtaining outpatient care at 13
clinic sites in DC. With over 8,000 participants enrolled as of December 2016, the Cohort pro-
vides a representative sample of the approximately 13,000 PLWH in DC who are in care [1].
The DC Cohort demographics are similar to those of all PLWH with respect to age, race/eth-
nicity, and sex; however, it is important to note that Cohort participants are those in care and
may not reflect the care patterns of all PLWH in DC. All consented participants have de-iden-
tified data electronically exported monthly to a centralized database [7]. Data elements
abstracted from sites’ electronic medical records (EMRs) include demographics, HIV risk
behaviors, diagnoses, laboratory tests, treatments, and procedures. An important element of
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the DC Cohort includes the periodic linkage of Cohort data to the DC Department of Health
(DOH) HIV/AIDS Hepatitis, STD, TB Administration (HAHSTA) surveillance databases
inclusive of molecular sequences from commercial laboratory reports, as well as location infor-
mation such as zip code of residence. In this study, GW, DC DOH and LabCorp collaborated
to further analyze these sequences beyond individual drug resistant variant calling–the only
information being currently reported back to DOH from LabCorp. The objectives of these
analyses were to: 1) characterize the diversity of HIV in the recent history of the DC epidemic,
2) identify drug resistant variants and sites under natural selection circulating in the DC popu-
lation, 3) identify potential transmission networks, and 4) characterize associations of epide-
miological factors with potential transmission networks, including geography.
Materials and methods
Ethics
Institutional Review Board (IRB071029) approval was obtained from The George Washington
University IRB (which serves as the IRB of Record for eight of the participating sites), the DC
DOH IRB, and the remaining site IRBs. Written informed consent was obtained and docu-
mented prior to conducting study procedures.
DC cohort
The DC DOH is one of 25 US jurisdictions funded by the Centers for Disease Control and Pre-
vention to conduct Molecular HIV Surveillance [8]. Through this surveillance program,
molecular sequence data generated by commercial laboratories is routinely sent to the DC
DOH and incorporated into the surveillance database. For the purposes of this analysis, resis-
tance data generated by LabCorp and sent to the DC DOH was incorporated into the DC
Cohort database through the aforementioned linkage process. Between January 1, 2011 and
March 31, 2015, 6,800 DC Cohort participants were enrolled in the study. The DC DOH
received 3,411 sequences collected between 2011 and 2015 on DC Cohort participants, which
were collected from 1,895 unique individuals. Using the most recently available post-DOH
linked data for participants consented by March 31, 2015 and sequenced by June 15, 2015,
2,858 sequences were available representing 1,740 unique participants (i.e., sequence coverage
is 25.6%). Descriptive and univariate analyses using Chi-square and Wilcoxon rank sum tests
in SAS v9.3 were conducted to describe participants and examine differences between Cohort
participants with and without sequence data (Table 1). The PROC FREQ function was used to
perform the Chi-Square tests and PROC NPAR1WAY function was used to perform the Wil-
coxon rank sum test. The sequence data were merged by participant ID with a limited set of
DC Cohort demographic and clinical variables (e.g., age, race, sex, risk factor, CD4 and viral
load count). The paired data were then analyzed in a de-identified manner using approaches
described below.
Sequencing
Sequencing-based analyses of regions of the HIV-1 polymerase (pol) gene were performed by
LabCorp for the detection of anti-retroviral resistance polymorphisms in regions encoding the
protease (PR; codons 1–99), reverse transcriptase (RT; codons 1–400), and integrase (INT;
codons 1–288) coding regions. In brief, HIV-1 RNA was recovered from plasma samples and
reverse transcription followed by nested polymerase-chain-reaction (RT-PCR) performed
using HIV-1 specific primer sets. Upon successful amplification, products were subjected to
Sanger sequencing (BigDye1 Terminator v3.1, ThermoFisher) and sequence reads analyzed
Phylodynamics and drug resistance of HIV in Washington, DC
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Table 1. Demographic and clinical characteristics of DC Cohort participants stratified by availability of sequence data.
Total N1 = 6,800 Participants Sequenced N1 = 1,740 Participants not Sequences N1 = 5,060 p-value2
Median Age (IQR)3 47 (36.4,54.6) 43 (31.6,50.7) 48.3 (38.5,55.7) < .0001
Race/ethnicity3
Non-Hispanic Black 5,317 (78.3) 1,486 (85.4) 3,831 (75.8)
Non-Hispanic White 982 (14.5) 148 (8.5) 834 (16.5)
Hispanic 334 (4.9) 77 (4.4) 257 (5.1) < .0001
Other 146 (2.1) 26 (1.5) 120 (2.4)
Unknown 12 (0.2) 3 (0.2) 9 (0.2)
Sex at Birth3
Male 4,938 (72.6) 1,162 (66.8) 3,776 (74.6)
Female 1,862 (27.4) 578 (33.2) 1,284 (25.4) < .0001
Country of Birth3
US 1,117 (82.6) 128 (75.3) 989 (83.7)
Non-US 235 (17.4) 42 (24.7) 193 (16.3) .0070
State of Residence3
DC 4,994 (73.4) 1,553 (89.2) 3,441 (68.0)
MD 1,298 (19.1) 155 (8.9) 1,143 (22.6) < .0001
VA 406 (6.0) 29 (1.7) 377 (7.4)
Other 102 (1.5) 3 (0.2) 99 (2.0)
HIV Risk Factor3
MSM 3,272 (48.1) 844 (48.5) 2,428 (48.0)
MSM/IDU 110 (1.6) 26 (1.5) 84 (1.6)
IDU 959 (14.1) 234 (13.4) 725 (14.3) < .0001
Heterosexual 1,961 (28.8) 555 (31.9) 1,406 (27.8)
Other4 262 (3.8) 39 (2.2) 223 (4.1)
Unknown 236 (3.5) 42 (2.4) 194 (3.8)
Co-morbidities3
Hepatitis C 820 (12.1) 115 (6.6) 705 (13.9) < .0001
Hepatitis B 235 (3.5) 41 (2.4) 194 (3.8) 0.0036
Syphilis 260 (3.8) 84 (4.8) 176 (3.5) 0.0113
Gonorrhea 40 (0.6) 25 (1.4) 15 (0.3) < .0001
Chlamydia 40 (0.6) 16 (0.9) 24 (0.5) 0.0362
Median Duration of Infection (yrs)(IQR)3 10 (5,17) 8 (2,15) 11 (6,17) < .0001
Median CD4 count (cells/μl)(IQR)3 513 (323,723) 348.5 (171,534) 566 (391.5,772) < .0001
Viral Load (copies/ml) (IQR)3
<200 3109 (59.9) 88 (5.9) 3,021 (81.9)
200–399 159 (3.1) 46 (3.1) 113 (3.1)
400–9999 733 (14.1) 473 (31.6) 260 (7.1) < .0001
10,000 1188 (22.8) 892 (59.5) 296 (8.0)
ARV Exposure3
Experienced 5,905 (86.8) 1,171 (67.3) 4,734 (93.6)
Naïve 345 (5.1) 117 (6.7) 228 (4.5) < .0001
Unknown 550 (8.1) 452 (26) 98 (1.9)
ARV Regimen Type3
PI-based 145 (2.4) 80 (1.8) 65 (4.2)
NRTI-based 234 (3.8) 152 (3.3) 82 (5.3)
NNRTI—based 13 (4.3) 7 (0.1) 6 (0.4) < .0001
INSTI-based 56 (0.9) 42 (0.9) 14 (0.9)
(Continued)
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using Sequencher DNA Sequence Analysis Software (Gene Codes Corp.). This process resulted
in the generation of two independent contiguous sequences of 1497bp of PR/RT (correspond-
ing to nucleotide positions 2253–3749 of HBX2CG [GenBank accession K03455]) and 864bp
int (corresponding to nucleotide positions 4230–5093 of HBX2CG).
Analyses
Sequence data were collected from HIV positive plasma samples from DC Cohort individuals
targeting either a portion of the PR/RT and/or int. We also included 170 subtype reference
sequences from the Los Alamos HIV database (http://www.hiv.lanl.gov/) to assign sequences
to particular subtype clades. Sequence data were aligned using MAFFT [9]. The best-fit model
of molecular evolution [10] was estimated from the data using jModelTest [11]. A maximum
likelihood phylogenetic estimate [12] was made using RAxML and 3 codon-position partitions
[13] with the best-fit model for each partition. Nodal support was estimated using the boot-
strap approach with 1,000 replicates [14]. Bayesian trees were also inferred using MrBayes [15]
and 3 codon-position partitions. We ran four chains (one cold and three heated) for 4x107
generations sampling every 2,000 steps for the int region and for 108 generations sampling
every 4,000 steps for the PR/RT region. Each run was repeated twice. Convergence and mixing
of the Markov chains were assessed in Tracer [16]. Phylogenetic transmission (infection) clus-
ters [17] were defined as those clades with bootstrap proportions >70% and posterior proba-
bilities >0.95. Transmission chains were also assessed using a recently described network
approach [18, 19] implemented in HIV-Trace (http://test.datamonkey.org/hivtrace). We used
genetic distance thresholds of 0.01 substitutions/site for identifying potential transmission
partners (see [18]).
HIV subtype B relative genetic diversity (i.e., population size over time) was inferred in
BEAST [20] using the PR/RT sequence data for all infected individuals born in the US. We
assume that these patients were also infected in the US. No sequence data were available for int
from US born patients. We used the GMRF Bayesian Skyride model [21], the HKY substitu-
tion model with gamma-distributed among-site rate heterogeneity, and a relaxed clock (log-
normal) model of rate of substitution [22]. We used the date of HIV-1 diagnosis to calibrate
the analysis and a normal prior with mean = 0.001 and SD = 0.0005 for ucld.mean. We per-
formed two runs 2x107 generations long sampling every 1,000 generations. Parameter uncer-
tainty was summarized in the 95% highest posterior density (HPD) intervals. All output
generated by BEAST was analyzed in Tracer [23].
Table 1. (Continued)
Total N1 = 6,800 Participants Sequenced N1 = 1,740 Participants not Sequences N1 = 5,060 p-value2
Dual-Class 3,069 (50.4) 2,270 (50.1) 799 (51.3)
ARV Resistance3
At least one PI 874 (13.9) 210 (7.9) 664 (18.3) < .0001
At least one NRTI 1,687 (26.8) 537 (20.2) 1,150 (31.6) < .0001
At least one NNRTI 1,645 (26.1) 660 (24.8) 985 (27.1) 0.0446
Other 24 (0.4) 19 (0.7) 5 (0.1) 0.0002
1Represents total number of Cohort participants enrolled through March 31, 2015. Totals may not sum to N due to missing data
2Chi-square or Wilcoxon test
3Data at the time of first sequence
4Perinatal, blood transfusion, hemophilia/coagulation disorder
https://doi.org/10.1371/journal.pone.0185644.t001
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HIV-1 subtype identification was done using the REGA subtyping tool [24, 25] and vali-
dated via phylogenetic analyses above. Haplotype diversity (h), the number of segregating sites
(S), nucleotide diversity (π), Watterson genetic diversity (θ) and recombination rate (r) were
estimated using DnaSP v. 5.10.1 [26]. Nucleotide ambiguities in the alignment were arbitrarily
resolved for these analyses. We identified drug resistant mutations by BLASTing [27] nucleo-
tide sequences against the Stanford HIV Drug Resistance Database (https://hivdb.stanford.
edu) using the HIVdb Program. We then identified nucleotide positions under positive selec-
tion using Fast Unconstrained Bayesian AppRoximation (FUBAR) [28], while accounting for
recombination GARD [29, 30]. These analyses were carried out in HyPhy [31].
Because the HIV sequences are related through an hierarchical evolutionary history,
they are not independent and typical genotype to phenotype associations cannot be per-
formed without taking the dependence structure into account [32]. We intended to use
treescanning [33] for the analyses, but found that there was insufficient resolvable structure
for int data set and although there were several large clades for PR/RT, there was no resolu-
tion between them at the base of the tree (i.e., low bootstrap values and posterior probabili-
ties for clade structure among these large clades). Therefore, among the few clades large
enough for statistical inference, we treated each clade as independent and conducted sim-
ple contingency table tests for association with sex, race and risk behavior where each clade
was treated as a separate factor and the remaining sequences were grouped into one factor
using a permutation chi-square test [34]. We used the chisq.test function in the core “stats”
package of R [35] with the simulate.p.value option. We generated 100 million Monte Carlo
permutations [36] for each test to obtain empirical p-values. To increase the number of
cases per cell in our chi-square tests, we limited the risk category to the two main risk types
(HRH, IDU and MSM). Because MSM and HRH are highly correlated with sex, we also
analyzed gender excluding MSM.
Results
Samples
We paired sequence data with the most recently available post-DOH linked demographic and
clinical data for participants consented by March 31, 2015 and sequenced by June 15, 2015.
We collected 601 partial int sequences and 2,810 partial PR/RT sequences from 223 partici-
pants and 1,659 participants, respectively, with a few participants being sequenced for both
genes. All sequences have been deposited in GenBank under accession numbers MF455515 –
MF457397. Aggregated demographic and clinical information (race, sex, age, risk factor, viral
load, CD4+ count, sequence date, HIV diagnosis date, and zip code) for participants are
shown in Table 1 along with a comparison between DC Cohort participants who had
sequences available to those without sequences. Our data came from participants who resided
predominantly in Washington DC (73.4%) and had dominant HIV risk factors of MSM
(48.1%) and heterosexual (28.8%). Participants with sequence availability were significantly
more likely to be younger, black, female, non-US born, and DC residents (p<0.0001 for all)
compared to those without sequence data. Slightly more participants with sequences were
infected through heterosexual sexual contact, and a higher proportion had a history of hepati-
tis C, syphilis, gonorrhea, and chlamydia co-infections at the time of sequencing (p<0.05 for
all). Participants with sequences had a shorter duration of infection, lower CD4 counts, higher
viral loads, and were less likely to be treatment experienced (p<0.0001 for all). Among those
on ARVs, a higher proportion of those sequenced were on dual-class regimens and had a
lower prevalence of resistance to PIs, NRTIs, and NNRTIs (p<0.001 for all).
Phylodynamics and drug resistance of HIV in Washington, DC
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HIV-1 diversity
Our subtyping analysis of int found that 220 of the participants were infected with subtype B
virus and identified three additional subtypes: A (1 individual), C (1), and G (1). The PR/RT
sequences were also heavily subtype B (1,557 of 1,659 participants), but with a greater diversity
of other subtypes including: AG (9 individuals), CD (1), BF (2), A (7), C (32), D (4), F (1), G
(3), J (1), AK (1), BA (1), BD (29), BF (7), DB (1) and unknown (3) (see also Fig 1).
All the DNA sequences from the same individual comprised identical replicates, hence we
only used one representative per individual for our analyses. The subtype B PR/RT gene
showed higher diversity rates, substitution rates (estimated as in [37]) and minimum number
of recombinant events than the subtype B int gene, but lower recombination/gen rates
(Table 2). Watterson genetic diversity (θ) for subtype B int was lower in the IDU group com-
pared to subtype B HRH and MSM likely due to the smaller sample size of the IDU (Table 2).
For the subtype B PR/RT sequence data, we also included perinatally infected participants and
that group had the highest nucleotide diversity, θ and non-synonymous substitution rates
despite its smaller sample size.
No noticeable differences in diversity and substitution rates were observed among subtypes
B, BD, and C for all the indices compared except for recombination per gene, which was about
three times higher for subtype BD compared to the other two subtypes.
Drug resistance
A total of 38 subtype B int sequences (2 HRH, 3 IDU and 20 MSM, and 13 “other risk”)
showed at least one DRM with an overall prevalence (HIV sequences including at least one
DRM/total number of sequences) of 17.3%. Thirty-five IN Major mutations and 26 IN Acces-
sory mutations were detected (Table 3). A total of 584 subtype B PR/RT sequences (215 HRH,
28 IDU, 232 MSM, 26 PER and 83 “other risk”) showed at least one DRM with a prevalence of
39.1%. NRTI, NNRTI and RT SDRMs included the highest proportions of resistant individuals
(301 to 461) and total DRM (557 to 931) and unique DRM (59 to 80) (Table 3). A total of 10
subtype BD PR/RT sequences (1 HRH, 8 MSM and 1 “other risk”) showed at least one DRM
with a prevalence of 34.5%. NRTI, NNRTI and RT SDRMs also included the highest propor-
tions of resistant individuals (6 to 10) and total DRM (10 to 22) and unique DRM (7 to 14)
(Table 3). Finally, a total of 8 subtype C PR/RT sequences (3 HRH and 5 “other risk”) showed
at least one DRM with a prevalence of 25.0%. NNRTI and RT SDRMs included the highest
proportions of resistant individuals (7) and total DRM (12 to 13) and unique DRM (9 to 12)
(Table 3). It is important to highlight that since only 6.7% of the patients in our cohort are
treatment naïve, we cannot confirm that these DRM are actually being transmitted. Amino
acid mutations counted as a DRM for each subtype and gene region are also presented in S1
Table.
Subtype B int DRM caused amino acid changes in 11 different codons while Subtype B PR/
RT DRM caused amino acid changes in 72 different codons (Table 3). Similarly, subtype BD
and C PR/RT DRM caused amino acid changes in 13 and 19 different codons, respectively.
These codons did not correspond to those inferred by FUBAR as being positively selected (8
and 12 amino acids in the int and PR/RT genes, respectively), except codon 140 in PR/RT,
which matched in both analyses. Positively selected sites included 8 amino acids for Subtype B
int (72, 201, 206, 218, 227, 230, 265 and 283), 14 for Subtype B PR/RT (12, 13, 19, 35, 37, 59, 79,
95, 136, 140, 203, 236, 301 and 312), 2 for Subtype BD PR/RT (136 and 312) and 5 for Subtype
C PR/RT (19, 65, 236, 274 and 275).
Phylodynamics and drug resistance of HIV in Washington, DC
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Fig 1. Cladogram of the PR/RT gene showing risk factors, ethnicities, subtypes and sex in four concentric rings. Main phenotypes within each ring
are represented with different colors. Well-supported clades comprised of >10 HIV sequences are also indicated in red.
https://doi.org/10.1371/journal.pone.0185644.g001
Phylodynamics and drug resistance of HIV in Washington, DC
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Phylodynamics and transmission networks
The past demographic analysis of DC subtype B PR/RT sequences from US born patients in
BEAST (Fig 2) indicates that HIV relative genetic diversity has not decreased significantly
over the last 25 years, despite an increasing prevalence of HIV infection earlier on in the
epidemic followed by more recent decreases in HIV incidence rates [1, 38]. Additionally
BEAST analyses aggregating HIV sequences by the two main sexual orientations of their
hosts (MSM and HTR) generated similar Skyride plots to that presented in Fig 2. Our ML
phylogenies and bootstrap analysis (70% support) grouped 13.5% of the int sequences into
14 phylogenetic clusters comprised of 2 to 3 sequences, while 39.0% of the PR/RT sequences
grouped into 203 phylogenetic clusters comprised of 2 to 32 sequences (S1 Fig, S2 Fig and
S3 Fig). These clusters were subsequently confirmed by our Bayesian analyses at a P0.95.
Higher proportions of clustered sequences were found in zip codes where HIV prevalence is
highest (r = 0.607; P<0.00001) with southeastern Washington, DC zip codes, being the
highest (Fig 3). A network approach (HIV-Trace) grouped 3.6% of the int sequences into 4
clusters of 2 sequences and 10.6% of the PR/RT sequences into 76 clusters of 2–7 sequences
(Fig 4). Hence, this approach identified fewer and smaller clusters compared to the ML-
bootstrap approach.
Table 2. HIV DNA polymorphism and drug resistant mutations (DRM).
Diversity Substitutions Recombination DRM
N S h Pi θ (W) Pi(s) Pi(ns) R/gene Rm Total (relative %)
SubB
Int
ALL 220 434 220 0.054 0.084 0.188 0.024 1133 100 38 (17.3)
HRH 78 345 78 0.053 0.081 0.185 0.023 831 83 2 (2.6)
IDU 13 180 13 0.051 0.067 0.174 0.024 3134 37 3 (23.1)
MSM 71 350 71 0.054 0.084 0.190 0.024 1178 85 20 (28.2)
PR/RT
ALL 1557 720 1556 0.064 0.090 0.222 0.028 975 149 584 (39.1)
HRH 512 614 512 0.063 0.088 0.220 0.028 1210 141 215 (38.5)
IDU 85 456 85 0.055 0.089 0.187 0.024 348 111 28 (32.6)
MSM 605 636 604 0.065 0.090 0.228 0.028 1304 143 232 (36.4)
PER 37 424 37 0.070 0.099 0.215 0.039 385 101 26 (68.4)
SubBD
PR/RT
ALL 29 353 29 0.067 0.088 0.239 0.029 2872 89 10 (34.5)
HRH 8 199 8 0.066 0.075 0.231 0.030 4363 37 1 (3.4)
MSM 18 294 18 0.067 0.083 0.243 0.028 1293 61 8 (27.6)
SubC
PR/RT
ALL 32 354 32 0.066 0.086 0.243 0.027 957 91 8(25.0)
HRH 16 273 16 0.066 0.080 0.236 0.029 1895 69 3 (9.4)
Diversity (N = sequences, S = segregating sites, h = haplotypes, Pi = nucleotide diversity, θ = Watterson genetic diversity), substitutions (Pi(s) =
synonymous, non-synonymous Pi(ns)), recombination (R) (R/gen = R per gen, and Rm = minimum number of recombinant events) rates. Total and relative
(total/N) proportion (%) of HIV strains including DRM. MSM = Men who have sex with men, HRH = heterosexuals, IDU = intravenous drug users,
PER = perinatal
https://doi.org/10.1371/journal.pone.0185644.t002
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Phenotypic associations
We found five well-supported (70% bootstrap proportion and0.95 posterior probability) PR/
RT clades of 11 to 32 HIV sequences. None of the clades showed exclusive mapping of a particular
risk group (Fig 1). However, our chi-square analyses detected a strong association (P<0.00001)
between those five clades and risk (MSM, IDU and HRH) and sex (Table 4), still highly significant
after a Bonferroni threshold for multiple tests of P<0.0167. Because MSM and HRH are so highly
correlated with sex, the sex significant results may be due to correlation with risk factor. There-
fore, we re-ran the test for sex excluding MSM (Table 4) and the evidence for a sex effect dropped
dramatically (P = 0.095), suggesting that the sex association was likely due to its correlation with
the most common risk categories. The other clinical variables were almost constant across clades
(e.g., race/ethnicity) or showed low numbers of cases per cell in our chi-square test (e.g., IDU).
Previous HIV studies in British Columbia (Canada) [39] and Switzerland [40] using intra-
patient or inter-patient sampling detected higher numbers of viral sequences falling within
clusters (3120–4431, (55–57% of all sequences)) than our study (647 (39.0%) of the PR/RT
sequences). Similarly, HIV epidemics in those two studies were dominated by 3–5 clusters of
1051–107 sequences and 14–17 clusters of 29–88 sequences. The HIV DC population was
grouped into 203 phylogenetic clusters of 2 to 32 PR/RT sequences, of which only 5 clusters
comprised 11–32 individuals. Ongoing work by our group including intra-patient sequences
from multiple patients generated via high-throughput (MiSeq) technology and covering a
larger geographic area (DC and neighboring states) will allow us to apply some on the method-
ologies (e.g., patristic distances) in [39, 40] to identify transmission clusters and consider mul-
tiple clinical co-variables simultaneously.
Discussion
Molecular surveillance and subtype diversity
The predominant HIV-1 subtype circulating among a subgroup of DC Cohort participants
comprised of mainly Non-Hispanic Blacks from 2011–2015 was subtype B, which accounted
Table 3. Drug resistant mutations.
Sub B – int Sub B – PR/RT Sub BD – PR/RT Sub C – PR/RT
S TM UM S TM UM S TM UM S TM UM
IN Major 24 35 17 - - - - - - - - -
IN Accessory 25 26 6 - - - - - - - - -
PR Major - - - 87 154 31 0 0 0 1 1 1
PR Accessory - - - 72 107 22 0 0 0 2 2 2
NRTI - - - 301 557 80 6 13 9 3 4 4
NNRTI - - - 410 663 69 6 10 7 7 13 12
PR SDRMs - - - 90 186 26 0 0 0 1 1 1
RT SDRMs - - - 461 931 59 10 22 14 7 12 9
PI TSMs - - - 33 34 11 0 0 0 1 1 1
NRTI TSMs - - - 52 59 13 1 1 1 1 1 1
NNRTI TSMs 14 15 12 1 1 1 0 0 0
DRM Codons 11 72 21 22
FUBAR Codons 8 14 2 5
Sequences (S), Total Mutations (TM) and Unique Mutations (UM) conferring resistance to antiretroviral drugs (IN Major to NNRTI TSMs) for genes int and
PR/RT in HIV subtypes (Sub) B, BD and C. DRM amino acid codons and codons under adaptive selection (FUBAR) are also listed
https://doi.org/10.1371/journal.pone.0185644.t003
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for 98.7% of the infections for int and 93.9% for PR/RT. Subtype B is also the predominant sub-
type in the US and Western Europe. We also detected another 15 subtypes that accounted for
the remaining sequences. A study by Kassaye et al. [41] also focused on HIV diversity in DC
used pol sequences collected from 641 individuals enrolled between 1994–2013 and showed a
higher frequency of non-subtype B sequences of HIV (88.5% subtype B and 11.4% non-B
HIV-1 subtypes). These differences could be due to demographic and clinical characteristics of
the participants in each cohort, changes in the dynamics of HIV in DC over the different time
frames of the two studies and/or the fact that the Kassaye et al. study surveyed over a period of
time that was double the timeframe of this study. HIV prevalence among ethnic minorities is
very high in DC, much less among the heterosexual white population, indicating that the HIV
epidemic is concentrated in key populations defined by sexual orientation and ethnicity. Yet,
nearly all patients harbored subtype B viruses, which suggests that the local epidemic amongst
ethnic minorities was seeded in the US and is at present not primarily driven by importation
from sub-Saharan Africa or other parts of the world where non-B subtypes circulate. The find-
ing of a small proportion of patients with non-subtype B virus, nonetheless, highlights the cul-
tural diversity of DC and the immigration of persons from other areas of the world. Higher
diversity of non-B HIV-1 subtypes has been reported in other immigrant-rich North Ameri-
can cohorts on the East Coast such as Rhode Island (8.3%) [42], Maryland (12.9%) [6], and
Fig 2. Bayesian skyride plot of HIV-1 subtype B PR/RT past population dynamics in US born patients. Black lines show the median estimate and
blue lines the 95% high posterior density limits of the relative genetic diversity over time.
https://doi.org/10.1371/journal.pone.0185644.g002
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New York City (43.4%) [43]. Similarly, the prevalence of non-B infections has increased from
5.9% in 2006 to 8.5% in 2013 in 7 US states (Colorado, Connecticut, Michigan, New York,
Fig 3. Geographic distribution of transmission networks by zip code overlaid on Washington DC map with rates of
persons living with diagnosed HIV in DC. Only zip codes containing4 HIV sequences that fall into a ML cluster (70%
bootstrap support) are shown.
https://doi.org/10.1371/journal.pone.0185644.g003
Fig 4. PR/RT network (HIV-Trace) of Washington DC HIV-1 isolates showing risk factors and
ethnicities.
https://doi.org/10.1371/journal.pone.0185644.g004
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South Carolina, Texas, and Washington) [44]. Lower rates, however, of non-B subtypes have
been reported for other Southeastern US states like North Carolina [45], which is consistent
with the national average prevalence of non-B subtypes (3.27%) estimated in 2011 [46].
Our estimates of int and PR/RT genetic diversity in subtype B viruses from DC were rela-
tively high (e.g., θ = 0.08–0.09, for all main subtypes) compared to other US subtype B strains
available in Los Alamos HIV database for int (θ = 0.075) and PR/RT (θ = 0.067). This suggests
that the HIV epidemic in DC is likely to be mature and that extensive exchange between risk
groups has been ongoing for years, which is also supported by our phylodynamic results as dis-
cussed below. High HIV genetic and subtype diversity is of concern as it complicates vaccine
development by increasing the chances for the evolution of vaccine resistance or the failure for
specific epitopes to work against broad diversity [47].
Our population estimators of genetic diversity, recombination, and selection showed differ-
ences between patients grouped by risk factor for some estimators. This may suggest differ-
ences in transmission and HIV-1 dynamics among risk groups. HIV Subtype B in perinatally
infected participants showed higher levels of diversity compared to other risk groups likely
due to the uniqueness of mother-infant transmission in perinatal infections (i.e., potentially
high HIV effective population size) and exposure to many different ARV regimens.
Our phylodynamic analyses of the US born subtype B sequences showed that the relative
genetic diversity of the DC viral population has not significantly decreased over the last 25
years. This is consistent with previous phylodynamic analyses of US subtype B sequences col-
lected between 1981 and 2006 [47]. More importantly, the epidemic persists among certain
groups like MSM, where infection rates are still very high and continue to be a source of con-
tinued transmission [1, 3, 47]. Therefore, department of health prevention efforts should con-
tinue to focus on high-risk groups as well as the general population [1, 48].
Phylogenetic structure of HIV-1 in Washington DC
Our phylogenetic analyses of subtype B sequences did not reveal clear evidence that HIV-1
populations in DC are structured by any of the epidemiological and clinical factors studied.
These results agree with previous subtype B star-like phylogenies reported for DC [41]. Geo-
graphically broader phylogenetic studies across the US also showed lack of phylogenetic struc-
turing based on transmission type, sociodemographic factors, and geographic location [47].
Keele et al. [49], for example, showed that viral env genes evolving from individual transmitted
or founder HIV-1 subtype B viruses generally exhibited a star-like phylogeny, such as the one
observed in North American viruses [47]. Given the maturity of the HIV-1 epidemic in DC
and the fact that the virus is thought to mutate at a rate of 1% per year [50, 51], the possibility
exists that different clades could have emerged in different wards or high-risk groups in the
city. Indeed, phylogenetic structuring based on these factors has been observed before between
Table 4. Chi-square tests of association between phylogenetic clades and demographic variables.
Risk Sex Sex w/o MSM
Clade Total (% HRH) Total (% Female) Total (% Female)
1 11 (18.2%) 11 (0%) 2 (0%)
2 20 (70%) 25 (48%) 16 (68.8%)
3 20 (100%) 22 (81.8%) 21 (85.7%)
4 10 (100%) 11 (63.6%) 10 (70%)
5 12 (0%) 13 (7.7%) 1 (100%)
P-value <1.00E-08 9.50E-07 0.095
https://doi.org/10.1371/journal.pone.0185644.t004
Phylodynamics and drug resistance of HIV in Washington, DC
PLOS ONE | https://doi.org/10.1371/journal.pone.0185644 September 29, 2017 13 / 20
subtypes in, for example, Africa [52] and Asia [53], and within subtypes in, for example, Viet-
nam [54] and China [55]. But contrary to what happened in those HIV/AIDS epidemics, our
star-like gene genealogies of HIV-1 in Washington DC suggest the DC epidemic expanded
uniformly (i.e., no phylogenetic structure) across the metropolitan area and across the epide-
miological risk types [56, 57].
Transmission networks
The extent to which transmission of HIV-1 is clustered is not clear. Some studies [58–69]
report high clustering (24 to 65%) levels, while others [18, 47, 67] show much lower values (7
to 17%) for the same subtypes and transmission routes. Our comprehensive phylogenetic anal-
yses of HIV-1 from DC show moderate proportions of subtype B infections (13.5% to 39.0%
depending on the gene) falling into clusters, confirming that transmission chains play a role in
HIV-1 transmission and spread of HIV in DC [41]. Previous studies of HIV-1 clustering in
DC and North America reported values of ~17% [41, 47], but a recent study of 86 patients in
Chicago showed levels of 36% [69]. Moreover, differences in clustering have also been
observed between subtypes, transmission routes, mental health and geographic regions [47,
62, 63, 69]. Our phenotypic association testing (chi-square) showed significant (P<0.00001)
association between PR/RT clusters and risk factor (transmission group), suggesting that MSM
and HRH may comprise largely independent transmission networks in the DC area, as seen in
other US states [44, 70].
Evolution of drug resistance
We detected a high prevalence of Drug Resistance Mutations (DRM) for both subtype B int
(17.1%) and PR/RT (39.1%) with similar prevalence across risk groups except for among het-
erosexuals when looking at int, (2.6%) and perinatally infected participants when looking at
PR/RT (68.4%). High rates of DRM were also detected in subtype BD (34.5%) and C (25.0%)
for PR/RT. PR/RT prevalence rates reported in this study are higher than those previously
reported for the DC area in 1994–2013 using pol sequences [41]. DRM rates higher than 50%
are frequently observed in large sequence databases in Europe (e.g., UK, http://www.hivrdb.
org.uk and Switzerland, www.shcs.ch) when similar patient groups are considered (i.e., ART
experienced). This finding may also reflect patient selection. Future analyses should determine
if DRMs of current treatment regimens cluster, and if there is evidence for increasing preva-
lence of DRMs based on current treatment regimens in the DC area. Similarly, studies includ-
ing only naïve patients are needed to determine to what extent these DRM are actually being
transmitted in the DC area.
Finally, we also detected 8 int and 12 PR/RT amino acids under adaptive selection. These
correspond to sites evolving in the DC HIV-1 subtype B population that have not been fixed in
HIV-1 as those conferring drug resistance. These amino acid sites involved positions that, in
the future, may confer resistance to antiretrovirals if they become fixed in the population and
could be helpful in informing ARV regimen choices.
Conclusions
Routinely collected commercial sequences are useful for examining transmission dynamics
and can provide an historical context for the HIV epidemic. Our ability to combine them with
surveillance, clinical, and demographic indicators enhances their utility in understanding
transmission patterns and geospatial distribution. Given the large number of sequences ana-
lyzed, the data presented in this study inform our understanding of the molecular epidemiol-
ogy of HIV infection in Washington DC. Moreover, they help lay the foundation for future
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work in which molecular and epidemiologic data could be used synergistically to target public
health interventions to interrupt HIV transmission networks.
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